Syros Pharmaceuticals, Inc. (SYRS)

Syros Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-144.49	-164.57	-94.65	-86.56	-84.04	-75.44
Depreciation & Amortization	1.96	2.33	2.97	3.02	3.04	2.72
Share-Based Compensation	9.89	10.43	11.41	10.35	10.94	9.84
Other Operating Activities	28.74	42.11	-42.79	-26.35	12.7	2.62
Operating Cash Flow	-103.9	-109.71	-123.07	-99.54	-57.36	-60.25
Capital Expenditures	1.55	1.29	-1.24	-1.25	-3.34	-12.53
Change in Investments	36.89	36.05	68.43	-51.41	50	0.79
Investing Cash Flow	38.45	37.34	67.19	-52.65	46.66	-11.73
Share Issuance / Repurchase	43.53	43.53	119.9	70.82	103.78	61.56
Debt Issued / Paid	-0.01	-0.07	-0.59	-0.27	39.38	-0.21
Other Financing Activities	-0.27	-	11.74	-0.04	-0.21	4.64
Financing Cash Flow	43.25	43.46	131.05	70.51	142.95	65.99
Net Cash Flow	-22.21	-28.91	75.17	-81.68	132.25	-6
Free Cash Flow	-102.35	-108.42	-124.31	-100.79	-60.7	-72.78
Free Cash Flow Margin	-1466.15%	-1091.17%	-835.39%	-429.09%	-402.17%	-3672.10%
Free Cash Flow Per Share	-2.63	-3.83	-9.84	-16.12	-13.18	-18.09

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).